Maria Stensland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Stensland has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alisa E. Dewan
Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
1 shared publication - Anika Langer
Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway
1 shared publication - Ben Davidson
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway
1 shared publication - Calum Leitch
Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway
1 shared publication - Christiane Helgestad Gjerde
Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway; Department of Obstetrics and Gynecology, Haukeland University Hospital, Haukelandsbakken 15, 5021, Bergen, Norway
1 shared publication - Christopher Forcados
Faculty of Medicine, University of Oslo, Sognsvannsveien 9, 0372, Oslo, Norway; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Ullernchausséen 64, 0379, Oslo, Norway
1 shared publication
Latest Publications
- Open Access
- 2 February 2026
- Published by Elsevier in EBioMedicine
- Vol. 124, 106135
A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response
- 2 February 2026
- Published by Elsevier in EBioMedicine
- Vol. 124, 106135
Open AccessA 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response
- Open Access
- 19 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (20)
IFN-γ is a direct driver of crypt hyperplasia in celiac disease
Crypt hyperplasia is a key feature of celiac disease (CeD) and several other small intestinal inflammatory conditions. Analysis of the gut epithelial crypt zone by mass spectrometry–based tissue proteomics revealed a strong IFN-γ signal in active CeD. This signal, hallmarked by increased expression of MHC molecules, was paralleled by diminished expression of proteins associated with fatty acid metabolism. Crypt hyperplasia and the same proteomic changes were observed in WT mice administered IFN-γ. In mice with conditional KO of the IFN-γ receptor in gut epithelial cells, these signature morphological and proteomic changes were not induced with IFN-γ administration. IFN-γ was thus a driver of crypt hyperplasia in CeD by acting directly on crypt epithelial cells. The results are relevant to other enteropathies with involvement of IFN-γ.
- 19 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (20)
Open AccessIFN-γ is a direct driver of crypt hyperplasia in celiac disease
Crypt hyperplasia is a key feature of celiac disease (CeD) and several other small intestinal inflammatory conditions. Analysis of the gut epithelial crypt zone by mass spectrometry–based tissue proteomics revealed a strong IFN-γ signal in active CeD. This signal, hallmarked by increased expression of MHC molecules, was paralleled by diminished expression of proteins associated with fatty acid metabolism. Crypt hyperplasia and the same proteomic changes were observed in WT mice administered IFN-γ. In mice with conditional KO of the IFN-γ receptor in gut epithelial cells, these signature morphological and proteomic changes were not induced with IFN-γ administration. IFN-γ was thus a driver of crypt hyperplasia in CeD by acting directly on crypt epithelial cells. The results are relevant to other enteropathies with involvement of IFN-γ.